We are delighted to announce that we have signed a Letter of Intent with iNGENū to carry out the first-in-human study of our natural, psilocybin-based medicine, KRN-101.
The study will be carried out in Melbourne, Australia, and including the collection of all clinical outputs, will be carried out over 8 weeks with an expected completion in Q3 2023.
Today we've published a corporate update for all those that have supported Albert Labs so far. We're progressing well in our mission to treat cancer-related distress with our medicine KRN-101. Read all about our progress in our latest press release via the link in our bio.
Today, we are pleased to announce we have filed a patent application for our scalable drug manufacturing process.
"This milestone demonstrates the Company's in-house biochemical engineering expertise and simultaneously establishes Albert Labs as a market leader in the controlled production and scaling of pharmaceutical quality, natural tryptamine-based medicines." - Dr. Michael Raymont, CEO Albert Labs
Read the full press release via our Linktree in our bio.
End-of-life anxiety is an urgent and under-treated area of healthcare, which is why we are focused on helping people suffering from cancer with their mental health at a time when they need it most.
Back in May, we welcomed Professor Sara Tai to our team of experts. Professor Tai is an experienced practitioner, trainer, and supervisor of transdiagnostic approaches for working with people with serious mental health problems and their families; providing one-to-one interventions, group interventions, and family work.
The recent and significant spike in psychedelic research is set to accelerate for as long as psychedelics continue to show promise in treating mental health conditions.
As Dr. Malcolm Barratt Johnson identifies, cancer-related distress is an under-treated are of healthcare that needs addressing urgently, which is why Albert Labs is using Real-World Evidence in a bid to provide accelerated access to safe and effective medicines.
Dr. Curry holds a PhD in Environmental Toxicology and is highly knowledgeable in a range of laboratory techniques, including microbial cultivation and screening, chemical analysis, method validation, safety testing, regulatory compliance and study design.
In May of this year, we were granted a Health Canada Licence - something that is critical to fulfilling our promise of providing accelerated access to mental health medicines for cancer patients with urgent and unmet needs.
